ClinicalTrials.gg
CompletedNCT02062645Updated Mar 28, 2017Results posted

Study of Efficacy and Safety of CVAA489 in Hypertensive Patients

A Phase 4 interventional study of amlodipine/valsartan in Essential Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 8 sites in Turkey. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2017-03-28.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
115
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing amlodipine in Essential Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Amlodipine · Essential Hypertension.

Enrollment
28th of 34
115 · median 314
Started
2014
with 6 others
Phase 4
7 of 34
1 open now
Registered
15th of 34
by date
Lead sponsor
3 of 34
Novartis Pharmaceuticals

Among the 34 studies testing amlodipine in Essential Hypertension, this one is the 28th largest by enrollment, is one of 7 that started in 2014, is one of 7 in phase 4, and was the 15th registered.

Essential Hypertension

480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

1 of the 34 studies testing amlodipine in Essential Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About amlodipine

Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing amlodipine in Essential Hypertension, or all of them as a file.
02

Study summary

The population that will be included in this study, will be regular Turkish hypertensive patients who are expected to consume sodium in high amounts. It is hypothesized that, in that population, amlodipine/valsartan will be effective at the same rate of blood pressure (BP) control rate as expected from literature.

03

Conditions studied

  • Essential Hypertension

Keywords

  • essential hypertension
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, above 18 years of age
  • Diagnosis of essential hypertension
  • Newly diagnosed,
  • Previously untreated, or Currently untreated (not on regular antihypertensive treatment during the previous at least 1-month period)
  • Written

Exclusion criteria

Exclusion Criteria:

  • Known or suspected secondary hypertension
  • lower than 30 mL/min
  • Use of any other hypertension treatments during the enrollment and need for using the related treatments during the study phase
  • History of to any of the study drugs or to drugs of similar chemical classes. (i.e. valsartan, amlodipine, hydrochlorothiazide)
  • History of of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or .
  • Use of other drugs within 5 half-lives of enrollment, or within 30 days until the expected PD effect has returned to baseline, whichever is longer.Pregnant or nursing (lactating) women
  • Other protocol-defined inclusion/exclusion criteria may apply.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
115 participants (actual)

Study arms

  • Experimental
    amlodipine/valsartan

    All patients will receive amlodipine/valsartan 5/160 mg daily in screening and up titrated to amlodipine/valsartan 10/160 mg daily at visit 2 (day 30) if their hypertension can not be controlled. The duration of treatment period is 8 weeks.

    Drug: amlodipine/valsartan

Interventions

  • Drugamlodipine/valsartan

    Drug pages: Amlodipine · Valsartan

    Fixed combination of amlodipine and valsartan in tablet; 5/160/mg, 10/160 mg

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Blood Pressure (BP) <140/90 mmHg at Week 4 and 8

    Control rate of BP defined as BP lower than 140/90 mmHg at office visits

    Time frame: At week 4 and 8

Secondary outcomes

  1. Systolic Blood Pressure (SBP) at Baseline, Week 4 and 8

    Change in systolic blood pressure measured in office from baseline at week 4 and 8.

    Time frame: baseline, week 4, week 8

  2. Diastolic Blood Pressure (DBP) at Baseline, Week 4 and 8

    Change in diastolic blood pressure measured in office from baseline at week 4 and week 8.

    Time frame: baseline, week 4, week 8

  3. Percentage of Participants With High Sodium Intake and Blood Pressure (BP) <140/90 mmHg at Week 4 and 8

    Control rate of BP is defined as blood pressure lower than 140/90 mmHg at office visits in patients with high sodium intake (\>100 mEq/day)

    Time frame: At week 4 and 8

  4. SBP and DBP in Patients With High Sodium Intake at Week 4 and 8

    Change in systolic and diastolic blood pressure measured in office from baseline at week 4 and 8.

    Time frame: At week 4 and 8

07

Results

Posted Mar 28, 2017

Participant flow

One hundred thirty patients were screened and 115 were enrolled into the trial.

Participant flow — Overall Study
MilestoneAmlodipine/Valsartan
Started115
Completed100
Not completed15
Withdrew: Adverse event2
Withdrew: Protocol violation8
Withdrew: Lost to follow-up5

Outcome measures

PrimaryPercentage of Participants With Blood Pressure (BP) <140/90 mmHg at Week 4 and 8

Control rate of BP defined as BP lower than 140/90 mmHg at office visits

Time frame:
At week 4 and 8
Reported as:
Number · Percentage of Participants
Percentage of Participants With Blood Pressure (BP) <140/90 mmHg at Week 4 and 8
Percentage of ParticipantsAmlodipine/Valsartan
Week 4 Systolic (n=100)47.0
Week 4 Diastolic (n=100)78.0
Week 4 Overall Blood Pressure(n=100)45.0
Week 8 Systolic(n=91)70.3
Week 8 Diastolic (n=91)82.4
Week 8 Overall Blood Pressure (n=91)67.0
Week 8 Systolic (LOCF) (n=100)68.0
Week 8 Diastolic (LOCF) (n=100)81.0
Week 8 Overall Blood Pressure (LOCF) (n=100)65.0
SecondarySystolic Blood Pressure (SBP) at Baseline, Week 4 and 8

Change in systolic blood pressure measured in office from baseline at week 4 and 8.

Time frame:
baseline, week 4, week 8
Reported as:
Mean · mmHg
Systolic Blood Pressure (SBP) at Baseline, Week 4 and 8
mmHgAmlodipine/Valsartan
Systolic blood pressure (SBP) Day 0 (n=100)164.3 ± 13.2
Systolic blood pressure (SBP) Week 4 (n=100)140.17 ± 14.05
Systolic blood pressure (SBP) Week 8 (n=91)134.04 ± 13.51
Systolic blood pressure (SBP) Week 8 LOCF (n=100)134.71 ± 13.37
Decrease in Systolic Week 4 (n=100)24.15 ± 18.18
Decrease in Systolic Week 8 (n=91)30.22 ± 18.25
Decrease in Systolic BP Week 8 LOCF (n=100)29.61 ± 17.81
SecondaryDiastolic Blood Pressure (DBP) at Baseline, Week 4 and 8

Change in diastolic blood pressure measured in office from baseline at week 4 and week 8.

Time frame:
baseline, week 4, week 8
Reported as:
Mean · mmHg
Diastolic Blood Pressure (DBP) at Baseline, Week 4 and 8
mmHgAmlodipine/Valsartan
Diastolic blood pressure (DBP) Day 0 (n=100)96.66 ± 12.68
Diastolic blood pressure (DBP) Week 4 (n=100)82.0 ± 9.88
Diastolic blood pressure (DBP) Week 8 (n=91)81.04 ± 8.66
Diastolic blood pressure (DBP) Week 8 LOCF (n=100)81.37 ± 8.69
Decrease in Diastolic BP Week 4 (n=100)14.66 ± 12.58
Decrease in Diastolic BP Week 8 (n=91)15.54 ± 13.19
Decrease in Diastolic BP Week 8 LOCF (n=100)15.29 ± 12.73
SecondaryPercentage of Participants With High Sodium Intake and Blood Pressure (BP) <140/90 mmHg at Week 4 and 8

Control rate of BP is defined as blood pressure lower than 140/90 mmHg at office visits in patients with high sodium intake (\>100 mEq/day)

Time frame:
At week 4 and 8
Reported as:
Number · Percentage of participants
Percentage of Participants With High Sodium Intake and Blood Pressure (BP) <140/90 mmHg at Week 4 and 8
Percentage of participantsAmlodipine/Valsartan
Week 4 (n=70)68.6
Week 8 (n=64)64.1
Week 8 LOCF (n=70)62.9
SecondarySBP and DBP in Patients With High Sodium Intake at Week 4 and 8

Change in systolic and diastolic blood pressure measured in office from baseline at week 4 and 8.

Time frame:
At week 4 and 8
Reported as:
Mean · mmHg
SBP and DBP in Patients With High Sodium Intake at Week 4 and 8
mmHgAmlodipine/Valsartan
SBP at Week 4 (n=70)140.01 ± 13.67
SBP at Week 8 (n=64)134.20 ± 13.24
SBP at Week 8 LOCF (n=70)134.84 ± 13.17
DBP at Week 4 (n=70)81.73 ± 10.26
DBP at Week 8 (n=64)81.23 ± 8.80
DBP at Week 8 LOCF (n=70)81.47 ± 8.91

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Amlodipine/Valsartan—3/110 (2.7%)76/110 (69.1%)
Most frequent serious events
Most frequent serious events
EventAmlodipine/Valsartan
DeathGeneral disorders1/110
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/110
NephrolithiasisRenal and urinary disorders1/110
Most frequent other events
Showing 10 of 16
Most frequent other events
EventAmlodipine/Valsartan
Left ventricular dysfunctionCardiac disorders34/110
Left ventricular hypertrophyCardiac disorders30/110
Mitral valve incompetenceCardiac disorders16/110
Aortic valve incompetenceCardiac disorders10/110
Tricuspid valve incompetenceCardiac disorders8/110
Urine sodium increasedInvestigations8/110
AnaemiaBlood and lymphatic system disorders7/110
MicroalbuminuriaRenal and urinary disorders6/110
Diastolic dysfunctionCardiac disorders5/110
Left atrial dilatationCardiac disorders4/110

Baseline characteristics

The baseline population was the ITT (intent to treat) population defined as: met all entry criteria, received study drug and had at least one blood pressure measurement after Visit 1 (Day 0)

Age, Continuous
Age, Continuous(years)Amlodipine/Valsartan
Mean55.06 ± 11.22
Sex: Female, Male
Sex: Female, Male(Participants)Amlodipine/Valsartan
Female55
Male45
Systolic blood pressure
Systolic blood pressure(mmHG)Amlodipine/Valsartan
Mean164.3 ± 13.2
Diastolic blood pressure
Diastolic blood pressure(mmHg)Amlodipine/Valsartan
Mean96.7 ± 12.7
Heart rate
Heart rate(beats/min)Amlodipine/Valsartan
Mean80.15 ± 10.00
Body mass index
Body mass index(kg/m^2)Amlodipine/Valsartan
Mean31.19 ± 5.32
08

Study locations

8 sites
  • Novartis Investigative Site
    Ankara, 06100, Turkey
  • Novartis Investigative Site
    Canakkale, Turkey
  • Novartis Investigative Site
    Fatih / Istanbul, 34098, Turkey
  • Novartis Investigative Site
    Kinikli / Denizli, 20070, Turkey
  • Novartis Investigative Site
    Kocaeli, 41380, Turkey
  • Novartis Investigative Site
    Malatya, 44280, Turkey
  • Novartis Investigative Site
    Mersin, 33079, Turkey
  • Novartis Investigative Site
    Talas / Kayseri, 38039, Turkey
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2014, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2014
First posted
Feb 14, 2014
Start
Feb 2014
Primary completionActual
Sep 2015
CompletionActual
Sep 2015
Results first posted
Mar 28, 2017
Last update
Mar 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02062645
Responsible party
Sponsor
First posted
Feb 14, 2014
Start date
Feb 2014
Primary completion
Sep 2015
Completion
Sep 2015
Results posted
Mar 28, 2017
Last update
Mar 28, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Amlodipine · Valsartan

Start the discussion